# Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer

> **NCT00004888** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 84 (actual)

## Conditions studied

- Recurrent Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** pegylated liposomal doxorubicin hydrochloride
- **DRUG:** docetaxel
- **BIOLOGICAL:** trastuzumab
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00004888
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** 2008-04
- **Final completion:** 2009-05
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2014-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004888, "Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00004888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*